Evidence map›Paper›PMID 41344852›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Phase 1 Study of [

Erik S Mittra, Lilja B Solnes, Astrid A M van der Veldt, Jeffrey Wong, Luigi Aloj, Michael C Heinrich, Christopher T Chen, Steven P Rowe, Tessa Brabander, Simon Pacey and 5 more

Abstract readClinical Trial, Phase IMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The novel [RSC advances · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Erik S MittraDivision of Molecular Imaging and Therapy, Department of Radiology, Oregon Health & Science University, Portland, Oregon; mittra@ohsu.edu.
Lilja B SolnesDivision of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Astrid A M van der VeldtDepartment of Radiology and Nuclear Medicine and Department Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Jeffrey WongDepartment of Radiation Oncology, City of Hope National Cancer Center, Duarte, California.
Luigi AlojDepartment of Radiology, University of Cambridge, Cambridge, United Kingdom.
Michael C HeinrichDivision of Hematology and Medical Oncology, Portland VA Health Care System and Oregon Health & Science University, Portland, Oregon.
Christopher T ChenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Steven P RoweMolecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Tessa BrabanderDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Simon PaceyDepartment of Oncology, Clinical School, University of Cambridge, Cambridge, United Kingdom.
Paola AimoneNovartis Pharma AG, Basel, Switzerland.
Dhrubajyoti PathakNovartis Pharma AG, Basel, Switzerland.
Lars BlumensteinNovartis Biomedical Research, Basel, Switzerland.
Yongmin LiuNovartis Pharma Co., Ltd., Beijing, China; and.
Andrei IagaruDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California.

Funding

National Succinate Dehydrogenase-deficient GIST Translational Research and Clinical Trial ConsortiumU01CA278470 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOHN Walter GLOD, Jason Keith Sicklick · 2024 to 2026
$1.8M
Novel models for functional profiling of germline SDH variants associated with cancerR21CA263400 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HEINRICH, MICHAEL C · 2021 to 2022
$320k
BLRD VA I01 BX005358Cancer Research UK C9685/A25117NCI NIH HHS R21 CA263400NCI NIH HHS U01 CA278470
6 · The paper itself

Abstract

Gastrin-releasing peptide receptor (GRPR) is overexpressed in a range of tumor types, making it an attractive candidate for novel treatment approaches. NeoB binds to GRPR with high affinity and can be radiolabeled with

Indexed as

Gene Expression Regulation, NeoplasticLutetiumNeoplasmsReceptors, BombesinSafetyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadioisotopesRadiometryRadiopharmaceuticalsLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsReceptors, Bombesin[177Lu]Lu-NeoBgastrin-releasing peptide receptorlutetiumradiopharmaceutical therapysolid tumors

Identifiers

PMID41344852
PMCPMC12866383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.